Skip to content

house · Committee report

H. Rept. 118-764

MANDATING EXCLUSIVE REVIEW OF INDIVIDUAL TREATMENTS ACT

2024-11-22

Committees

Associated legislation

Text

Purpose and Summary

H.R. 133 clarifies that national coverage determinations for drugs and biologics under the Medicare program must be made with respect to each drug or biologic, not with respect to a class of drugs or of biologics.

Background and Need for Legislation

H.R. 133 would ensure that prospectively, any national coverage decision that the Centers for Medicare and Medicaid (CMS) makes will only apply to that specific therapy and not an entire class of drugs. Medicare includes several pathways to coverage for items and services, including for drugs and breakthrough medical devices. The national coverage determination (NCD) process provides coverage of an item or service nationally. Currently, CMS makes NCDs on an entire class of drugs. This legislation would ensure that CMS must make NCDs on individual drugs.

Committee Action

On September 19, 2023, the Subcommittee on Health held a hearing on H.R. 133. The title of the hearing was ``Examining Policies to Improve Seniors' Access to Innovative Drugs, Medical Devices, and Technology.'' The Subcommittee received testimony from: Dora Hughes, MD, MPH, Acting Director, Center for Clinical Standards and Quality, Acting Chief Medical Officer, U.S. Centers for Medicare and Medicaid Services; and John Dicken, Director, Health Care--Public Health and Private Markets, U.S. Government Accountability Office. On November 15, 2023, the Subcommittee on Health met in open markup session and forwarded H.R. 133, as amended, to the full Committee by voice vote. On December 6, 2023, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 133, as amended, favorably reported to the House by a record vote of 42 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held a hearing and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 133 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, the following is the cost estimate provided by the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974: Summary: On December 6, 2023, the House Committee on Energy and Commerce ordered 41 pieces of legislation to be reported. This document provides estimates for 21 bills in that package that are related to health care and consumer protection. Generally, the bills in this group that would affect direct spending would: Limit beneficiary cost sharing for certain prescription drugs and add certain drugs to the group of products covered by the Medicare home infusion benefit; Prohibit pharmacy benefit managers (PBMs) from collecting certain fees from prescription drug manufacturers and require PBMs to provide additional information to Medicare Part D plans (which provide prescription drug coverage); Allow Part D plans more flexibility to add biosimilar biological products to their formularies and to change the cost-sharing status of reference biological products; Temporarily increase Medicare payment rates for durable medical equipment (DME); and Provide mandatory funding for implementation of certain provisions in several bills. Estimated Federal cost: The costs of the legislation fall within budget functions 550 (health) and 570 (Medicare). Basis of estimate: For this estimate, CBO assumes that the bills will be enacted near the middle of fiscal year 2024 and that the estimated amounts will be appropriated each year. This cost estimate does not include any effects of interactions among the bills. If all 21 bills were combined and enacted as a single piece of legislation, the effects could be different from the sum of the separate estimates. Direct spending: Enacting 10 bills in the group would affect direct spending over the 2024-2034 period (see Table 1). TABLE 1.--ESTIMATED EFFECTS ON DIRECT SPENDING OF HEALTH CARE LEGISLATION, AS ORDERED REPORTED BY THE HOUSE COMMITTEE ON ENERGY AND COMMERCE ON DECEMBER 6, 2023 -------------------------------------------------------------------------------------------------------------------------------------------------------- By fiscal year, millions of dollars-- ------------------------------------------------------------------------------------------------------------- 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2024-2029 2024-2034 -------------------------------------------------------------------------------------------------------------------------------------------------------- INCREASES OR DECREASES (-) IN DIRECT SPENDING H.R. 2880: Budget Authority...................... 0 0 0 -29 -39 -31 -31 -28 -26 -24 -18 -99 -226 Outlays............................... 0 0 0 -29 -39 -31 -31 -28 -26 -24 -18 -99 -226 H.R. 3842: Budget Authority...................... 0 * * * * * * * * * * * * Outlays............................... 0 * * * * * * * * * * * * H.R. 4881: Budget Authority...................... 0 0 0 40 77 88 100 106 113 134 136 165 754 Outlays............................... 0 0 0 0 77 88 100 106 113 134 136 165 754 H.R. 5372: Budget Authority...................... 0 -9 -12 -12 -14 -12 -14 -16 -17 -20 -19 -59 -145 Outlays............................... 0 -9 -12 -12 -14 -12 -14 -16 -17 -20 -19 -59 -145 H.R. 5380: Budget Authority...................... 15 0 0 0 0 0 0 0 0 0 0 15 15 Outlays............................... 13 1 1 0 0 0 0 0 0 0 0 15 15 H.R. 5385: Budget Authority...................... 55 0 0 -55 -75 -60 -60 -55 -50 -46 -35 -135 -381 Outlays............................... 49 4 2 -55 -75 -60 -60 -55 -50 -46 -35 -135 -381 H.R. 5386: Budget Authority...................... 0 0 * * * * * * * * * * * Outlays............................... 0 0 * * * * * * * * * * * H.R. 5393: Budget Authority...................... 0 6 0 0 0 0 0 0 0 0 0 6 6 Outlays............................... 0 6 0 0 0 0 0 0 0 0 0 6 6 H.R. 5397: Budget Authority...................... 0 0 -9 -13 -15 -14 -15 -17 -17 -20 -19 -37 -139 Outlays............................... 0 0 -9 -13 -15 -14 -15 -17 -17 -20 -19 -37 -139 H.R. 5555: Budget Authority...................... 144 1 0 0 0 0 0 0 0 0 0 145 145 Outlays............................... 144 1 0 0 0 0 0 0 0 0 0 145 145 -------------------------------------------------------------------------------------------------------------------------------------------------------- All amounts for outlays are estimates; except for H.R. 5380 and H.R. 5393, all amounts for budget authority are estimated. * = between -$500,000 and $500,000. H.R. 2880, the Protecting Patients Against PBM Abuses Act, would modify the rules with respect to certain fees that PBMs collect from prescription drug manufacturers. In Medicare Part D (which provides prescription drug coverage), sponsors of private insurance plans contract with the government to deliver benefits to Medicare beneficiaries. Those insurance plans usually contract with PBMs to negotiate with drug manufacturers, design formularies, and perform other administrative functions. A PBM can be owned by the plan sponsor or it can be an independent corporate entity. H.R. 2880 would prohibit PBMs from collecting service fees from manufacturers that are based on drug prices, manufacturer discounts, or formulary placement decisions. Under the bill, those fees would be specific dollar amounts based on the fair market value of a PBM's services. Under current law, PBMs can be compensated for services they provide to manufacturers, but compensation that exceeds the fair market value of a service must be classified as direct and indirect remuneration and reported to the Centers for Medicare & Medicaid Services (CMS). According to the Government Accountability Office, however, CMS does not routinely monitor how PBMs classify those fees.\1\ Under the bill, CMS and the Office of Inspector General would more closely monitor those classifications. --------------------------------------------------------------------------- \1\See Government Accountability Office, Medicare Part D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures, GAO- 19-498 (July 2019), Appendix III, www.gao.gov/products/gao-19-498. --------------------------------------------------------------------------- CBO estimates that manufacturers' service fees are roughly 1 percent of Part D retail spending under current law. CBO expects that under H.R. 2880, a portion of those fees would be reclassified as direct and indirect remuneration by PBMs and, because of stronger oversight, passed along to the sponsors of prescription drug plans. That action would reduce bid amounts for plans' expected benefit payments, which in turn would reduce spending in Part D. CBO estimates that the provision would decrease federal spending by $226 million over the 2024- 2034 period, or by roughly 1 percent of the amount expected to be collected in service fees over that period. H.R. 3842, the Expanding Access to Diabetes Self-Management Training Act of 2023, would allow more providers to refer eligible patients to diabetes self-management training covered by Medicare and would codify regulatory time limits on use of the training. CBO expects that enacting H.R. 3842 would result in more patients receiving such training, which would lead to increased Medicare spending. CBO expects that such training would reduce the use of acute-care services, at least partly offsetting that increase in costs. As a result, CBO estimates that enacting the bill would increase or decrease direct spending by less than $500,000 over the 2024-2034 period. H.R. 4881, a bill to amend title XVIII of the Social Security Act to limit cost sharing for drugs under the Medicare program, would limit cost sharing above the deductible to no more than the average net price for a drug, which is the list price minus after-sale discounts from the drug's manufacturer. From 2028 to 2034, CBO projects, less than 1 percent of Part D spending above the deductible under current law will be for drugs with cost sharing that exceeds net drug costs. Under the bill, CBO expects that some out-of-pocket spending by beneficiaries and some federal subsidies for low-income beneficiaries would shift onto Part D plans, which would increase the bids they submit to the federal government to cover expected benefits spending and therefore increase federal spending. CBO estimates that enacting H.R. 4881 would increase direct spending by $754 million over the 2024-2034 period. H.R. 5372, the Expanding Seniors' Access to Lower Cost Medications Act of 2023, would allow Part D plans to add biosimilar biological products to their formularies and change the cost-sharing status of a reference biological product after the first 60 days of a plan year. (A reference biological product is the approved product against which a proposed biosimilar product is compared.) Under current law, Part D plans must exempt beneficiaries who currently use reference biological products from changes in coverage and cost sharing for the remainder of the year. That restriction limits a plan's ability to promote use of a biosimilar product immediately following that product's entry to the market. CMS has proposed rules that overlap with the bill's provisions concerning formulary substitutions for biosimilar products.\2\ CBO's estimate of Medicare spending for those products under current law accounts for 50 percent of the effect of the proposed rules. As a result, CBO's estimate of the decrease in direct spending under H.R. 5372 is larger than it might be if CMS's rules had become final. --------------------------------------------------------------------------- \2\See Centers for Medicare & Medicaid Services, ``Medicare Program; Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications,'' Notice of Proposed Rulemaking, 88 Fed. Reg. 78476 (November 15, 2023), http://tinyurl.com/wv7yprfm; and ``Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Program, Medicare Cost Plan Program, Medicare Parts A, B, C, and D Overpayment Provisions of the Affordable Care Act and Programs of All-Inclusive Care for the Elderly; Health Information Technology Standards and Implementation Specifications,'' Notice of Proposed Rulemaking, 87 Fed. Reg. 79452 (December 27, 2022), http://tinyurl.com/3754c49x. --------------------------------------------------------------------------- Under the bill, the addition of biosimilar products to formularies could lead to a shift away from the use of reference biological products. CBO estimates that the government will spend about $10 billion over the 2024-2034 period to cover reference biological products under current law. CBO anticipates that under H.R. 5372 approximately 20 percent of the current use of reference biological products would be replaced by biosimilar products. The prices for biosimilar products are estimated to be 15 percent lower, on average, than the prices for the reference products. Using information about spending on both types of products under current law and adjusting for current regulatory proposals by CMS that would streamline coverage for biosimilar products, CBO estimates that enacting H.R. 5372 would decrease direct spending by $145 million over the 2024-2034 period. H.R. 5380, a bill to amend title XVIII of the Social Security Act to increase data transparency for supplemental benefits under Medicare Advantage, would provide $15 million in 2024 for the Department of Health and Human Services (HHS) to implement reporting requirements for supplemental benefits under Medicare Advantage plans. Based on historical spending patterns for HHS programs, CBO estimates that enacting H.R. 5380 would increase direct spending by $15 million over the 2024-2034 period. H.R. 5385, the Medicare PBM Accountability Act, would require pharmacy benefit managers to provide plan sponsors with information not furnished under current law. Part D plans have access to certain aggregate and drug-specific information from PBMs concerning prescriptions, prices, rebates, and out-of- pocket charges, but may lack information about PBM-affiliated entities and contractors, rationales for formulary decisions, and explanations for benefit designs that favor certain pharmacies. H.R. 5385 would require PBMs to report such information to Part D plans but also, subject to certain restrictions, would allow plans to audit PBMs' business practices and request other information. The bill would provide $55 million for HHS to implement those requirements. H.R. 5385 also would require PBMs to make their business practices clearer to Part D plans, thus promoting competition among PBMs. CBO estimates that the increased competition would reduce net spending for Part D by less than 0.1 percent over the 2024-2034 period--reducing federal spending by $436 million over that period. CBO estimates that the net effect of the bill would be a reduction in direct spending of $381 million over the 2024-2034 period. H.R. 5386, the Cutting Copays Act, would prohibit cost sharing for generic drugs for beneficiaries who are eligible for the low-income subsidy, which pays most or all of their premium and cost-sharing requirements. Under current law, plans have an option but not an obligation to do so. CBO expects that enacting the bill would increase the use of generic drugs, which would increase plan bid submissions for expected benefits payments and, therefore, federal spending. CBO expects that some of the increase would be offset by reduced spending on brand-name drugs and certain medical services. CBO estimates that enacting the bill would increase direct spending by less than $500,000 over the 2024-2034 period. H.R. 5393, a bill to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare Part D, and for other purposes, would provide $4 million in 2025 for CMS program management to implement pharmacy performance and quality measures for Part D and $2 million in that year to implement pharmacy transparency requirements. Based on historical spending patterns for CMS administrative costs, CBO estimates that enacting H.R. 5393 would increase direct spending by $6 million over the 2024-2034 period. H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023, would add drugs to the current Medicare benefit that allows patients to receive some drugs by infusion under nursing care at home. H.R. 5397 would allow other drugs to meet the statutory criteria for coverage in the home setting by establishing those products as suitable for delivery through a pump and requiring patients receiving those drugs also to receive regular nursing services. Based on its analysis of the beneficiary population and Medicare payment rates, CBO estimates that enacting the bill would reduce direct spending by $139 million over the 2024-2034 period, primarily because beneficiaries would bear a larger share of the cost of infusions that occur at home. Under current law, there is a cap on beneficiary cost sharing in outpatient hospital settings, which is where CBO expects that beneficiaries receive those drugs now. There is no equivalent cap for the home infusion benefit. CBO's estimate for H.R. 5397 is subject to considerable uncertainty. First, it is not known how many drugs would qualify for coverage under the bill. CBO's estimate focused on three products that industry and clinical experts mentioned as likely candidates, but the actual number could be larger or smaller. In addition, given that cost sharing could increase significantly for patients, it is not known how many beneficiaries would choose to receive home infusions.\3\ --------------------------------------------------------------------------- \3\CMS proposed a similar but not identical policy in a proposed rulemaking. In the regulatory impact analysis, CMS estimated that, for one product, beneficiaries' cost sharing would be about triple the amount if the product was received in a home setting. For more information, see Centers for Medicare & Medicaid Services, ``Medicare Program; Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) Policy Issues and Level II of the Healthcare Common Procedure Coding System (HCPCS),'' Notice of Proposed Rulemaking, 85 Fed. Reg. 70358 (November 4, 2020), http://tinyurl.com/29djdrvz. --------------------------------------------------------------------------- H.R. 5555, the DMEPOS Relief Act of 2023, would temporarily increase Medicare rates in some areas of the country for DMEPOS (durable medical equipment, prosthetics, orthotics, and supplies). Under current law, Medicare's payments for some equipment are based on competitive bidding among suppliers. CMS uses those results to set rates (either directly or through a blend with the historic fee schedule) in areas of the country where formal bidding has not occurred. Prior legislation directed CMS to use a blend of fee schedule and competitively bid rates in some areas of the country; the use of those blended rates expired at the end of calendar year 2023. Enacting H.R. 5555 would extend the use of those blended rates through calendar year 2024. Based on an analysis of historic claim spending, CBO estimates that the DME provision of the

Source: https://api.congress.gov/v3/committee-report/118/hrpt/764